StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

Equities research analysts at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Monday. The brokerage set a “sell” rating on the stock.

Oragenics Stock Down 0.9 %

NYSE:OGEN opened at $1.05 on Monday. Oragenics has a 1 year low of $0.97 and a 1 year high of $7.74. The firm has a 50 day moving average price of $1.47. The company has a market capitalization of $4.70 million, a PE ratio of -0.12 and a beta of 0.50.

Oragenics (NYSE:OGEN) last posted its earnings results on Wednesday, May 15th. The company reported ($0.70) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC acquired a new position in Oragenics, Inc. (NYSE:OGEN) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.